Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 1;35(6):589-594.
doi: 10.1097/QCO.0000000000000885. Epub 2022 Oct 7.

Novel agents in development for multidrug-resistant Gram-negative infections: potential new options facing multiple challenges

Radhika Arya  1 , Breanna S Goldner, Andrew F Shorr
Affiliations
Review

Novel agents in development for multidrug-resistant Gram-negative infections: potential new options facing multiple challenges

Radhika Arya et al. Curr Opin Infect Dis. .

Abstract

Purpose of review: To review novel antiinfective agents in development for multidrug-resistant (MDR) Gram-negative bacterial infections.

Recent findings: Four novel agents are in various phases of development (tebipenem, durlobactam-sulbactam, cefepime-taniborbactam, and xeruborbactam). Tebpipenem is an oral carbapenem with a recently completed phase III trial for complicated urinary tract infections while durlobactam-sulbactam represents a potential alternative for drug-resistant Acinetobacter baumannii . Cefepime-taniborbactam possesses in-vitro potency against a range of troubling pathogens and we await further information on a recently completed study on complicated urinary tract infection. Finally, xeruborbactam is an ultrabroad beta-lactamase inhibitor that can be paired with a range of intravenous and oral agents. It exhibits enhanced in-vitro activity against many MDR pathogens, including those resistant to newer, broader spectrum options. Data in humans with xeruborbactam are limited.

Summary: Each of the newer options reviewed possesses a unique range of in-vitro activity against select, challenging pathogens with some narrowly tailored and other broader in activity. Several have both oral and intravenous formulations. Two agents have presented data from recent phase III trials, whereas two are not as advanced in their clinical programs.

PubMed Disclaimer

References

    1. Bandić-Pavlović D, Zah-Bogović T, Žižek M, et al. Gram-negative bacteria as causative agents of ventilator-associated pneumonia and their respective resistance mechanisms. J Chemother 2020; 18:1–15.
    1. Luyt CE, Hékimian G, Koulenti D, et al. Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia. Curr Opin Crit Care 2018; 24:332–338.
    1. Zilberberg MD, Shorr AF, Micek ST, et al. Multidrug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care 2014; 18:596.
    1. Vincent JL, Sakr Y, Singer M, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA 2020; 323:1478–1487.
    1. Jain A, Utley L, Parr TR, et al. Tebipenem, the first oral carbapenem antibiotic. Expert Rev Anti Infect Ther 2018; 16:513–522.

MeSH terms